BTH has the access to FAIMS configuration tech and I suppose the data library/SW specifically targeting diseases. NASH may have some(?) connections into a Pharma. BLO is specifically targeting THC and other drugs with FAIMS, while BTH focuses on diseases. Configurations may differ and data libraries will certainly be different along with hardware and procedures being significantly different (?).
I doubt their markets cross except in base tech, SW and interfaces. BTH/BLO share that as we all invested in that research and testing. I sure would like a buyout of BTH/NASH by some Pharma, with FAIMS tech priced in. BLO is fighting their own race to use FAIMS for drug detection. Both are at least semi-finished, V3, which should eventually bring some value. Lots of folks using FAIMS. L3 bought IMSC partly for its FAIMS tech which brought me to BLO by accident @$.50 and then BTH @$.07. I think we are all here just to make money. Been pretty lucky flipping both.
The big issue here, is BTH under some form of the NASH/BTH BODs' control or does this BTH/NASH deal need shareholder a BTH vote? Then ???...JMHO...GLTA...
News 
Market Data 
Discover 
AI
